Efficacy | BALVERSA® (erdafitinib) HCP
Visualization of efficacy endpoints in oncology clinical trials
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | BioSpace
dMMR Recurrent or Advanced Solid Tumors | JEMPERLI (dostarlimab-gxly)
Durable Response Rate
Cell therapy doubles survival, response rates in advanced melanoma
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Overall response rate | Download Table
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Efficacy endpoints in Oncology
The overall response rate | Download Table
Zacks Small Cap Research - ONCS: New Data Provide Evidence that ImmunoPulse IL-12 Can Prime the Immune System
Response Rates for Waldenström Macroglobulinemia Improve With Use of New First-Line, Better-Tolerated Treatments - U.S. Medicine
Overall Response Rate | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Efficacy | BALVERSA® (erdafitinib) HCP
Forest plot of the comparison of overall response rate (ORR).
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
ORR (Objective Response Rate) and related statistics – Part 1
Durable Response Rate
Best Overall Response Rate (full analysis population) | Download Table
